Show simple item record

dc.contributor.authorKreitchmann, Regispt_BR
dc.contributor.authorOliveira, Fernando Rocha dept_BR
dc.contributor.authorSprinz, Eduardopt_BR
dc.date.accessioned2022-04-07T04:48:29Zpt_BR
dc.date.issued2021pt_BR
dc.identifier.issn1413-8670pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/236731pt_BR
dc.description.abstractDolutegravir (DTG) is amongst the most prescribed antiretrovirals worldwide and is recommended as first line regimen in most HIV treatment guidelines. Its use, although infrequently, had been associated to an increased chance of neural tube defects (NTD) in Botswana, Africa. Herein we describe two cases of NTD in women who conceived while taking DTG as part of their antiretroviral treatment in the city of Porto Alegre, Brazil.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofThe Brazilian journal of infectious diseases. Salvador. Vol. 25, no. 2 (Mar./Apr. 2021), 101572, 4 p.pt_BR
dc.rightsOpen Accessen
dc.subjectCOVID-19en
dc.subjectHIVpt_BR
dc.subjectGravidezpt_BR
dc.subjectNeural tube defectsen
dc.subjectPregnancyen
dc.subjectDefeitos do tubo neuralpt_BR
dc.subjectPorto Alegre (RS)pt_BR
dc.subjectDolutegraviren
dc.titleTwo cases of neural tube defects with dolutegravir use at conception in south Brazilpt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001137454pt_BR
dc.type.originNacionalpt_BR


Files in this item

Thumbnail
   

This item is licensed under a Creative Commons License

Show simple item record